Sandra Calvin, SVP, CHIEF ACCOUNTING OFFICER at Travere Therapeutics, Inc. (TVTX), sold 30,000 shares at $17.22 ($517K) on 2024-12-26, disclosed to the SEC on 2024-12-27.
Scheduled sale ($517k) by SVP, CHIEF ACCOUNTING OFFICER under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $17.22 | 15,000 | $258K | 50.0% |
| 2 | $17.22 | 15,000 | $258K | 50.0% |
| Total | $17.22 avg | 30,000 | $517K | 100% |
| Filing → |
| TVTX | SELL | 2026-02-03 | $139K | — | Filing → |
| TVTX | SELL | 2025-12-29 | $296K | — | Filing → |
| TVTX | SELL | 2025-12-16 | $105K | — | Filing → |